Madrigal falls on Phase II hypercholesterolemia readout

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) lost $14.46 (10%) to $131.53 on Thursday after reporting Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary

Read the full 303 word article

User Sign In